ATA189691A - Hpth-peptide, ihre herstellung und verwendung - Google Patents

Hpth-peptide, ihre herstellung und verwendung

Info

Publication number
ATA189691A
ATA189691A AT0189691A AT189691A ATA189691A AT A189691 A ATA189691 A AT A189691A AT 0189691 A AT0189691 A AT 0189691A AT 189691 A AT189691 A AT 189691A AT A189691 A ATA189691 A AT A189691A
Authority
AT
Austria
Prior art keywords
production
hpth peptides
hpth
peptides
Prior art date
Application number
AT0189691A
Other languages
English (en)
Original Assignee
Novartis Erfind Verwalt Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Erfind Verwalt Gmbh filed Critical Novartis Erfind Verwalt Gmbh
Publication of ATA189691A publication Critical patent/ATA189691A/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/635—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Otolaryngology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AT0189691A 1990-09-20 1991-09-20 Hpth-peptide, ihre herstellung und verwendung ATA189691A (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909020544A GB9020544D0 (en) 1990-09-20 1990-09-20 Improvements in or relating to organic compounds

Publications (1)

Publication Number Publication Date
ATA189691A true ATA189691A (de) 1997-10-15

Family

ID=10682494

Family Applications (1)

Application Number Title Priority Date Filing Date
AT0189691A ATA189691A (de) 1990-09-20 1991-09-20 Hpth-peptide, ihre herstellung und verwendung

Country Status (21)

Country Link
US (1) US5578567A (de)
EP (2) EP0490806A3 (de)
JP (1) JPH04247034A (de)
KR (1) KR920006003A (de)
AT (1) ATA189691A (de)
AU (1) AU8464791A (de)
CA (1) CA2051721A1 (de)
CH (1) CH683749A5 (de)
CS (1) CS285491A3 (de)
DE (1) DE4131232A1 (de)
FI (1) FI914398A7 (de)
FR (2) FR2666987A1 (de)
GB (2) GB9020544D0 (de)
IE (1) IE913296A1 (de)
IL (1) IL99521A0 (de)
IT (1) IT1255258B (de)
LU (1) LU88006A1 (de)
MX (1) MX9101175A (de)
NO (1) NO913668D0 (de)
PT (1) PT99007A (de)
ZA (1) ZA917528B (de)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3090353B2 (ja) 1991-09-17 2000-09-18 旭化成工業株式会社 パラチロイドホルモン類含有経鼻投与用乳剤
ES2129048T3 (es) * 1991-12-09 1999-06-01 Asahi Chemical Ind Composicion estabilizada de hormona paratiroide.
DE4203040A1 (de) * 1992-02-04 1993-08-05 Boehringer Mannheim Gmbh Neue parathormonfragmente, deren herstellung und diese enthaltende arzneimittel
CA2094217A1 (en) * 1992-04-17 1993-10-18 Yasutaka Igari Transmucosal therapeutic composition
US5977070A (en) * 1992-07-14 1999-11-02 Piazza; Christin Teresa Pharmaceutical compositions for the nasal delivery of compounds useful for the treatment of osteoporosis
AU672790B2 (en) * 1992-07-15 1996-10-17 Novartis Ag Variants of parathyroid hormone and its fragments
GB2269992A (en) * 1992-08-14 1994-03-02 Rh Ne Poulenc Rorer Limited Powder inhalation formulations
DK0679088T3 (da) 1992-09-29 2002-10-28 Inhale Therapeutic Syst Pulmonal levering af aktive fragmenter af parathyreoideaea hormon
US5482931A (en) * 1993-06-29 1996-01-09 Ferring Ab Stabilized pharmaceutical peptide compositions
US5496801A (en) * 1993-12-23 1996-03-05 Allelix Biopharmaceuticals Inc. Parathyroid hormone formulation
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6117455A (en) 1994-09-30 2000-09-12 Takeda Chemical Industries, Ltd. Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent
EP1283035A3 (de) * 1994-12-22 2003-03-19 AstraZeneca AB Parathyroidhormon enthaltende therapeutische Zubereitung zur Inhalation
JP3098401B2 (ja) * 1995-07-12 2000-10-16 株式会社エルティーティー研究所 経鼻投与用製剤
JP3263598B2 (ja) * 1995-11-01 2002-03-04 有限会社ドット 経鼻吸収用生理活性ペプチド組成物
CN1095681C (zh) * 1996-06-20 2002-12-11 久光制药株式会社 一种用于离子电渗疗法的装置结构
TW505654B (en) * 1996-07-30 2002-10-11 Hoffmann La Roche Synthesis of analogs of PTH and PTHrP
SE9702401D0 (sv) 1997-06-19 1997-06-19 Astra Ab Pharmaceutical use
EP1016412A4 (de) * 1997-07-22 2001-05-02 Chugai Pharmaceutical Co Ltd Zahnheilmittel mit pth
ES2320603T3 (es) 1997-07-30 2009-05-25 Emory University Sistemas de expresion, vectores, adn, proteinas de mineralizacion osea novedosos.
US7923250B2 (en) 1997-07-30 2011-04-12 Warsaw Orthopedic, Inc. Methods of expressing LIM mineralization protein in non-osseous cells
US6770623B1 (en) 1997-12-09 2004-08-03 Eli Lilly And Company Stabilized teriparatide solutions
MY120063A (en) † 1997-12-09 2005-08-30 Lilly Co Eli Stabilized teriparatide solutions
DE19756314C2 (de) * 1997-12-12 2000-06-29 Roland Bodmeier Zubereitung mit verlängerter Verweildauer am Applikationsort
JPH11246439A (ja) * 1998-03-02 1999-09-14 Hisamitsu Pharmaceut Co Inc 経粘膜用吸収促進剤
CN1065141C (zh) * 1998-05-20 2001-05-02 北京金源东和化学有限责任公司 通过鼻粘膜给药的药物制剂
US6623732B1 (en) * 1998-05-20 2003-09-23 Highchem Company, Ltd. Pharmaceutical formulation for nasal administration
US6150420A (en) * 1998-06-01 2000-11-21 Theramax, Inc. Method for enhanced brain delivery of bupropion
AU762145C (en) * 1998-08-26 2005-03-17 Teijin Limited Powdery pernasal compositions
JP2000239187A (ja) * 1999-02-22 2000-09-05 Dotto:Kk 経鼻吸収用組成物
JP2000247911A (ja) 1999-02-26 2000-09-12 Hisamitsu Pharmaceut Co Inc 大腸用吸収促進剤
MXPA01011283A (es) * 1999-05-03 2002-11-04 Battelle Memorial Institute Composiciones par aerosolizacion e inhalacion.
US6197328B1 (en) * 1999-08-20 2001-03-06 Dott Research Laboratory Nasally administrable compositions
ES2166278B2 (es) * 1999-09-14 2003-06-16 Univ Madrid Complutense Procedimiento de preparacion de polvos nasales por atomizacion utilizando excipientes insolubles y absorbentes como promotores de absorcion nasal.
AU2001244391B9 (en) * 2000-04-03 2006-10-05 Ventaira Pharmaceuticals, Inc. Devices and formulations
BR0112381A (pt) 2000-06-30 2003-05-06 Suntory Ltd Componente farmacêutico com base em hormÈnio da paratireóide humana e uma composição farmacêutica para administração intranasal compreendendo o componente
EP1343521A2 (de) * 2000-12-01 2003-09-17 Battelle Memorial Institute Verfahren zur stabilisierung von biomolekülen (z.b. insulin) in flüssigen formulierungen
DE10120200B4 (de) * 2001-04-24 2005-12-22 Infood Gmbh Schnupfpulver als Schnupftabakersatz
CA2486909A1 (en) * 2002-05-23 2003-12-04 Umd, Inc. Compositions and method for transmucosal drug delivery and cryoprotection
US7273889B2 (en) * 2002-09-25 2007-09-25 Innovative Drug Delivery Systems, Inc. NMDA receptor antagonist formulation with reduced neurotoxicity
AU2003282955A1 (en) * 2002-10-17 2004-05-04 Alkermes Controlled Therapeutics, Inc. Ii Microencapsulation and sustained release of biologically active polypeptides
GB0304636D0 (en) * 2003-02-28 2003-04-02 Britannia Pharmaceuticals Ltd Pharmaceutical composition for nasal delivery
US7683029B2 (en) * 2003-05-07 2010-03-23 Philip Morris Usa Inc. Liquid aerosol formulations containing insulin and aerosol generating devices and methods for generating aerosolized insulin
US20060052306A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. GRAS composition for enhanced mucosal delivery of parathyroid hormone
US20060127320A1 (en) * 2004-05-10 2006-06-15 Nastech Pharmaceutical Company Inc. Method of delivering parathyroid hormone to a human
US20060052305A1 (en) * 2004-05-10 2006-03-09 Nastech Pharmaceutical Company Inc. Method of treating osteoporosis using intranasal parathyroid hormone
US20060189533A1 (en) * 2004-05-10 2006-08-24 Nastech Pharmaceutical Company Inc. Stable pharmaceutical dosage forms of teriparatide
US7244709B2 (en) * 2004-05-10 2007-07-17 Nastech Pharamecutical Company Inc. Compositions and methods for enhanced mucosal delivery of parathyroid hormone
US7906137B2 (en) * 2004-05-21 2011-03-15 Mediplex Corporation, Korea Delivery agents for enhancing mucosal absorption of therapeutic agents
CN101005851A (zh) * 2004-07-14 2007-07-25 中外制药株式会社 含pth的经粘膜给药药剂
US20060069021A1 (en) * 2004-08-13 2006-03-30 Nastech Pharmaceutical Company Inc. Compositions and methods for intranasal administration of inactive analogs of PTH or inactivated preparations of PTH or PTH analogs
US7115561B2 (en) * 2004-09-22 2006-10-03 Patterson James A Medicament composition and method of administration
MX2007010244A (es) * 2005-02-23 2008-03-10 Johnson & Johnson Administracion intranasal de agentes activos al sistema nervioso central.
US20090136505A1 (en) * 2005-02-23 2009-05-28 Johanna Bentz Intranasal Administration of Active Agents to the Central Nervous System
MX2007015819A (es) * 2005-06-13 2008-02-22 Nastech Pharm Co Suministro de derivados peptidicos a traves de la mucosa.
WO2007044069A2 (en) * 2005-10-06 2007-04-19 Nastech Pharmaceutical Company Inc. Pth formulations and methods of use
WO2007044375A2 (en) * 2005-10-06 2007-04-19 Nastech Pharmaceutical Company Inc. Pth formulations and methods of use
US20070173447A1 (en) * 2005-10-25 2007-07-26 Nastech Pharmaceutical Company Inc. Method for treating osteoporosis by intranasal delivery of teriparatide with an anti-resorptive agent
WO2007059470A2 (en) 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
US20080051332A1 (en) * 2005-11-18 2008-02-28 Nastech Pharmaceutical Company Inc. Method of modulating hematopoietic stem cells and treating hematologic diseases using intranasal parathyroid hormone
US20080119408A1 (en) * 2006-07-07 2008-05-22 Nastech Pharmaceutical Company Inc. Pth formulations for intranasal delivery
WO2008065144A2 (en) * 2006-11-29 2008-06-05 Novartis Ag Galenic formulations of organic compounds
GB0715285D0 (en) * 2007-08-06 2007-09-12 Britannia Pharmaceuticals Ltd Improvements in or relating to powdered medicaments for nasal delivery
EP2106788A1 (de) * 2008-04-04 2009-10-07 Ipsen Pharma Flüssige und lyophilisierte Formulierungen
WO2011071480A1 (en) 2009-12-07 2011-06-16 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
JP5670430B2 (ja) * 2010-03-19 2015-02-18 第一三共株式会社 経鼻投与用組成物及びその製造方法
US10723716B2 (en) 2016-12-21 2020-07-28 New York University Alpha-helix mimetics as modulators of Abeta self-assembly
US11124479B2 (en) 2017-07-14 2021-09-21 New York University Oligopyrroles as antagonists of islet amyloid polypeptide oligomerization
US10500197B2 (en) 2017-07-18 2019-12-10 New York University Use of oligopyridylamides to inhibit mutant p53 amyloid formation and restore its tumor suppressor function
PH12022551856A1 (en) 2020-01-22 2024-01-03 Seelos Therapeutics Inc Reducing side effects of nmda antagonists
JP6947946B1 (ja) * 2020-05-11 2021-10-13 旭化成ファーマ株式会社 テリパラチド又はその塩を含有する安定な液状医薬製剤
US20240307504A1 (en) * 2021-01-21 2024-09-19 Nbo Pharma Llc Intranasal formulations and delivery of somatostatin mimetics and uses thereof
CA3209483A1 (en) * 2021-02-24 2022-09-01 Nbo Pharma Llc Methods and therapeutic combinations for treating idiopathic intracranial hypertension and cluster headaches

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3243358A1 (de) * 1982-11-24 1984-05-24 Rolf Dieter Prof.Dr. 3004 Isernhagen Hesch Synthetisches humanes (1-38) parathormon-fragment, verfahren zu seiner herstellung und die verwendung zur behandlung der osteoporose
GB8514090D0 (en) * 1985-06-04 1985-07-10 Sandoz Ltd Organic compounds
FR2550204B1 (fr) * 1983-08-05 1987-11-13 Toyo Jozo Kk Derives peptidiques de (nle8,nle1b, tyr34)-h-pth
GB2193891B (en) * 1986-08-18 1990-07-25 Sandoz Ltd Nasal pharmaceutical composition containing a somatostatin anologue.
JPS6360940A (ja) * 1986-09-01 1988-03-17 Toyo Jozo Co Ltd 白内障の予防または治療剤
JPS63243033A (ja) * 1987-03-31 1988-10-07 Toyo Jozo Co Ltd 経鼻投与組成物
US5059587A (en) * 1987-08-03 1991-10-22 Toyo Jozo Company, Ltd. Physiologically active peptide composition for nasal administration
NZ226557A (en) * 1987-10-15 1990-07-26 Syntex Inc Pharmaceutical compositions for the intranasal administration of a biologically active polypeptide in powder form and process for their preparation
GB2212062B (en) * 1987-11-13 1991-07-17 Isf Spa Pharmaceutical compositions containing a calcitonin and a glycyrrhizinate ab- sorption enhancer
JPH0242027A (ja) * 1988-08-02 1990-02-13 Minofuaagen Seiyaku Honpo:Goushi 経粘膜吸収促進剤及びこれを用いた経鼻投与剤
JPH02104531A (ja) * 1988-10-14 1990-04-17 Toyo Jozo Co Ltd 経鼻投与用生理活性ペプチド組成物
US5190748A (en) * 1988-11-22 1993-03-02 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
US5011678A (en) * 1989-02-01 1991-04-30 California Biotechnology Inc. Composition and method for administration of pharmaceutically active substances
JPH04504847A (ja) * 1989-03-08 1992-08-27 ザ　ユニバーシティ　オヴ　バージニア　パテント　ファウンデーション インスリン抵抗性糖尿病のための食事用補添物
IT8920486A0 (it) * 1989-05-12 1989-05-12 Isf Spa Composizioni farmaceutiche.
DE4039656A1 (de) * 1990-12-12 1992-06-17 Bissendorf Peptide Gmbh Arzneimittel, enthaltend das humane parathormon-fragment (1-37) in der form des amids oder ethylamids als aktiven wirkstoff
US5317010A (en) * 1991-10-10 1994-05-31 Peter K. T. Pang Parathyroid hormone analogues substituted at AA 25, 26, 27, and use in osteoporosis treatment

Also Published As

Publication number Publication date
EP0672682A1 (de) 1995-09-20
US5578567A (en) 1996-11-26
JPH04247034A (ja) 1992-09-03
FI914398L (fi) 1992-03-21
GB2248550A (en) 1992-04-15
GB2248550B (en) 1995-04-05
CS285491A3 (en) 1992-04-15
GB9020544D0 (en) 1990-10-31
ITRM910696A0 (it) 1991-09-18
NO913668D0 (no) 1991-09-18
LU88006A1 (fr) 1993-04-15
GB9120024D0 (en) 1991-11-06
FR2681326B1 (fr) 1995-06-16
IT1255258B (it) 1995-10-20
CA2051721A1 (en) 1992-03-21
EP0490806A2 (de) 1992-06-17
DE4131232A1 (de) 1992-03-26
PT99007A (pt) 1992-08-31
ITRM910696A1 (it) 1993-03-18
ZA917528B (en) 1993-03-22
IE913296A1 (en) 1992-02-25
FR2681326A1 (fr) 1993-03-19
MX9101175A (es) 1992-05-04
EP0490806A3 (en) 1992-09-23
AU8464791A (en) 1992-03-26
CH683749A5 (de) 1994-05-13
FI914398A0 (fi) 1991-09-18
FI914398A7 (fi) 1992-03-21
IL99521A0 (en) 1992-08-18
KR920006003A (ko) 1992-04-27
FR2666987A1 (fr) 1992-03-27

Similar Documents

Publication Publication Date Title
DE69529026D1 (de) Trehalose, ihre Herstellung und ihre Verwendung
DE69223476D1 (de) Cermets, ihre Herstellung und Verwendung
DE69328528D1 (de) D-Ketohexose-3-Epimerase, und seine Herstellung und Verwendung
ATE239693T1 (de) 3,3-diarylpropylamine , ihre verwendung und herstellung
DE68902203D1 (de) Schraubenabdeckungskonstruktionen und ihre herstellung.
DE59709806D1 (de) Cycloolefincopolymere, ihre verwendung und daraus hergestellte formkörper
DE69015788D1 (de) Thermistor und dessen herstellung.
ATA3589A (de) Neue isochinolinderivate, ihre herstellung und ihre verwendung
DE69008454D1 (de) Nitrolsothiolderivate, ihre Herstellung und Verwendung.
DE3879975D1 (de) Demethylavermectine und herstellung dazu.
DE69111507D1 (de) Isolationsmaterial und dessen Herstellung.
ATE335000T1 (de) Disulfid-vernetzte glycoprotein-hormone, ihre herstellung und verwendung
DE69027170D1 (de) Uracilderivate, ihre Herstellung und ihre Verwendung
DE59409541D1 (de) Bicyclen-derivate, ihre herstellung und verwendung
DE69521595D1 (de) Optisch-aktives Benzothiepin-Derivate, ihre Herstellung und Verwendung
DE59208576D1 (de) 3-Isoxazolylphenylverbindungen, ihre Herstellung und ihre Verwendung
DE59105838D1 (de) Dihydroxypropylsulfoethylcellulosen, ihre Herstellung und Verwendung.
DE3774718D1 (de) Benzothiazolylazolidine und ihre herstellung und verwendung.
DE69421172D1 (de) Synthetises detergensstueck und herstellung davon
DE69213362D1 (de) Elektrolyseur und Herstellung davon
ATE268760T1 (de) Neue carbonsäurederivate, ihre herstellung und verwendung
PT85396B (de) Neue 1,4-benzodiazepine ihre herstellung und verwendung
DE69304871D1 (de) Dicyanatpräpolymere, ihre Verwendung und Herstellung
DE68908389D1 (de) Amidofluoroverbindungen, ihre herstellung und ihre verwendung.
DE68919259D1 (de) N-Phenylimide, ihre Herstellung und Verwendung.

Legal Events

Date Code Title Description
A1J Withdrawal paragraph 166 lit. 6
UEP Publication of translation of european patent specification